recent
launch
document
burden
respiratori
infecti
diseas
australia
time
remind
full
impact
respiratori
infect
health
australian
multipl
specif
diseas
entiti
signific
right
import
complic
factor
cut
across
area
respiratori
health
document
outlin
dramat
mismatch
enorm
total
diseas
burden
rel
pauciti
effect
manag
strategi
first
instanc
mismatch
may
seem
surpris
reflect
case
home
truth
viral
infect
import
caus
respiratori
infect
yet
specif
diagnosi
rare
made
ii
antivir
therapi
exist
case
influenza
either
underus
overus
diagnost
ineffici
iii
approach
use
antibacteri
agent
guid
reason
cover
organ
miss
rather
treatment
regimen
target
particular
organ
iv
associ
diagnost
uncertainti
make
suffici
allow
immunocompromis
state
overexuber
immun
respons
respiratori
infecti
diseas
rid
v
current
antibiot
guidelin
encourag
approach
increasingli
cover
potenti
organ
depend
sever
ill
issu
lead
increas
direct
cost
individu
unnecessari
exposur
sideeffect
commun
exposur
antibiot
select
pressur
futur
antibiot
resist
financi
cost
indirect
cost
potenti
use
treatment
approach
consid
eg
antiinflammatori
immunemodifi
drug
develop
antibiot
guidelin
rid
progress
taken
home
truth
consider
guidelin
recommend
minim
antibiot
use
primari
pathogen
like
viru
maxim
antibiot
use
high
probabl
signific
bacteri
infect
individu
risk
stratif
accord
patient
comorbid
ill
sever
use
vari
degre
guidelin
physician
manag
patient
rid
encourag
best
individu
societi
antibiot
usag
concern
suggest
continu
approach
incorpor
new
valu
ad
inform
ensur
develop
futur
signific
improv
knowledg
manag
form
rid
addit
strategi
may
ad
benefit
priorit
ongo
antimicrobi
drug
develop
even
streamlin
regulatori
drug
approv
despit
mani
differ
syndrom
aetiolog
agent
cover
burden
respiratori
infecti
diseas
australia
document
present
overwhelm
theme
diagnost
ineffici
spite
advanc
molecular
technolog
exampl
numer
studi
shown
specif
microbi
diagnosi
routin
made
case
patient
hospit
communityacquir
pneumonia
although
number
approach
detail
microbiolog
molecular
test
studi
microbi
diagnosi
elud
us
approxim
half
patient
whether
uncommon
organ
test
common
organ
miss
overexuber
host
respons
known
diagnost
ineffici
lead
heavi
relianc
empir
treatment
strategi
also
contribut
lack
knowledg
diagnost
ineffici
handicap
innov
think
regard
manag
acut
rid
particularli
sever
ill
respond
empir
antimicrobi
therapi
current
relianc
empir
antibiot
strategi
cover
like
bacteri
pathogen
set
numer
guidelin
unavoid
short
term
given
current
diagnost
limit
respiratori
infect
syndrom
long
term
howev
need
move
away
almost
absolut
requir
empir
antibiot
rid
move
toward
target
antibiot
strategi
case
organbas
infect
achiev
need
consider
improv
develop
diagnost
tool
rid
tool
need
rapid
reliabl
avail
point
care
imposs
shown
develop
rapid
diagnost
test
help
stratifi
limit
antiretrovir
use
develop
countri
improv
sensit
specif
diagnost
assay
specif
respiratori
pathogen
also
requir
improv
sensit
would
enhanc
abil
avoid
use
antibacteri
viral
infect
improv
specif
would
enhanc
abil
use
specif
antibiot
andor
antivir
first
instanc
use
maximum
potenti
accord
pharmacodynam
principl
although
recent
develop
multiplex
polymeras
chain
reaction
assay
viral
atyp
bacteri
organ
enzymelink
immunosorb
assay
bacteri
antigen
eg
legionella
streptococcu
pneumonia
promis
area
requir
consider
basic
appli
research
even
logist
issu
associ
obtain
test
sampl
immedi
test
result
mean
empir
antibiot
continu
use
least
initi
rid
improv
diagnost
test
possibl
allow
treatment
subsequ
tailor
would
also
longerterm
benefit
epidemiolog
data
local
respiratori
infect
could
enhanc
decisionmak
regard
empir
antibiot
use
anoth
potenti
spinoff
enhanc
data
collect
would
better
understand
pathogenet
mechan
associ
specif
viru
bacteri
infect
inform
may
also
posit
influenc
develop
antimicrobi
pipelin
pharmaceut
compani
issu
relat
acut
respiratori
infect
otherwisehealthi
individu
appli
even
greater
degre
atrisk
group
person
either
underli
lung
diseas
eg
asthma
chronic
obstruct
pulmonari
diseas
copd
immun
impair
eg
elderli
immunodefici
syndrom
compar
rest
popul
atrisk
popul
suscept
wider
rang
infect
sever
diseas
given
infect
organ
often
greater
imper
make
specif
diagnosi
patient
riskbenefit
ratio
ongo
relianc
empir
antibiot
strategi
usual
accept
improv
sensit
specif
diagnost
assay
rid
shown
offer
dramat
benefit
clinic
manag
risk
patient
exampl
manag
hivaid
associ
opportunist
infect
revolution
last
year
approach
combin
quantit
viral
load
test
effect
antiretrovir
therapi
similarli
lung
organ
transplant
becom
commonplac
western
countri
one
commonest
infect
posttransplant
use
cytomegaloviru
cmv
pneumon
due
reactiv
ubiquit
dna
viru
twenti
year
ago
transplant
physician
reli
poorli
sensit
histopatholog
nonspecif
viral
cultur
diagnost
cmv
diseas
rel
blunt
treatment
approach
use
antivir
treatment
whole
field
transform
sensit
molecular
test
routin
appli
combin
focus
antivir
strategi
yield
better
result
rich
inform
regard
pathobiolog
event
first
subclin
cmv
reactiv
identifi
common
lung
allograft
henc
period
univers
prophylaxi
appropri
cmv
atrisk
recipi
lung
transplant
recipi
second
understand
dynam
cmv
reactiv
follow
cessat
antivir
immedi
direct
benefit
patient
ie
quantit
cmv
detect
determin
need
specif
antivir
use
indirect
benefit
subtl
reactiv
syndrom
could
relat
specif
immunolog
profil
longterm
lung
allograft
outcom
third
efficaci
specif
intervent
strategi
could
easili
monitor
conceptu
framework
extend
reactiv
dna
virus
posttransplant
case
lung
transplant
increasingli
use
delin
overal
influenc
commun
respiratori
rna
virus
lung
allograft
view
develop
novel
antivir
intervent
strategi
set
lung
transplant
potenti
direct
indirect
ie
allograft
reject
lifethreaten
consequ
respiratori
infect
import
drive
innov
manag
concept
relat
specif
exampl
lung
transplant
extend
gener
respiratori
condit
addit
diagnost
improv
manag
atrisk
patient
could
enhanc
obtain
diseasesuscept
inform
welldefin
atrisk
popul
eg
cystic
fibrosi
allerg
bronchopulmonari
aspergillosi
bronchiectasi
tuberculosi
even
immunosuppress
treatment
profil
inform
could
aid
decisionmak
term
whether
use
prophylact
preemptiv
antibiot
avoid
specif
acut
infect
syndrom
certain
atrisk
patient
group
strategi
alreadi
use
hivaid
inform
could
also
provid
insight
hostpathogen
interact
acut
condit
pneumonia
well
asthma
copd
acut
exacerb
chronic
progress
import
burden
respiratori
diseas
research
could
also
provid
greater
interpandem
influenza
yearli
public
health
concern
continu
associ
signific
morbid
mortal
despit
benefit
come
activ
influenza
surveil
network
nation
influenza
vaccin
strategi
avail
antivir
influenza
one
imagin
potenti
nightmar
scenario
may
result
new
influenza
pandem
eg
avian
influenza
particularli
emerg
viru
achiev
humantohuman
transmiss
retain
high
degre
pathogen
great
deal
govern
invest
pandem
flu
prepar
plan
around
world
protocol
invari
built
around
appropri
stage
plan
action
concentr
surveil
contain
antivir
strategi
earli
phase
epidem
outbreak
buy
much
time
possibl
appropri
vaccin
develop
distribut
subtli
also
great
deal
research
develop
aim
develop
novel
antivir
intervent
optim
vaccin
efficaci
product
clearli
everpres
threat
nation
futur
health
everi
effort
made
elimin
much
diagnost
manag
uncertainti
possibl
risk
pose
outbreak
sever
acut
respiratori
syndrom
sar
respons
marshal
newli
avail
technolog
time
success
isol
identifi
sequenc
new
strain
coronaviru
respons
record
time
achiev
view
fast
track
develop
effect
antivir
treatment
sar
final
potenti
threat
bioterror
also
led
governmentsponsor
dramat
align
molecular
scienc
new
technolog
provid
rapid
diagnost
test
suspici
sampl
conclus
daytoday
manag
rid
problem
learn
much
approach
infecti
diseas
complic
atrisk
individu
emerg
viral
threat
former
case
seem
becom
complac
empir
treatment
approach
compound
lack
knowledg
rel
blunt
approach
match
specif
condit
specif
treatment
latter
case
howev
indic
current
obtain
use
valuead
inform
begin
better
requir
sens
vision
priorit
identif
rid
import
health
prioriti
simultan
rais
awar
unmet
clinic
need
pose
respiratori
infect
across
mani
area
medicin
offer
clear
path
forward
focu
effici
coordin
futur
clinic
scienc
research
health
polici
initi
direct
reduc
current
futur
burden
rid
invest
today
reduc
burden
pay
futur
dividend
mani
time
us
irrespect
whether
becom
ill
